What is HC Wainwright's Estimate for AXSM FY2026 Earnings?

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Axsome Therapeutics to a loss of $2.71 per share from a projected loss of $4.10, while maintaining a Buy rating.
• The firm forecasts losses of $0.27 per share in Q4 2026 and $0.16 in Q1 2027, followed by earnings of $0.60 per share in Q2 2027. The broader analyst consensus for the current full year is a loss of $2.39 per share.
• Axsome reported a quarterly loss of $0.25 per share, beating the $0.63 loss analysts expected; revenue of $259.69 million was up 51.9% year over year.

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities researchers at HC Wainwright boosted their FY2026 earnings per share estimates for Axsome Therapeutics in a research report issued to clients and investors on Monday, November 9th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($2.71) per share for the year, up from their prior estimate of ($4.10). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.39) per share. HC Wainwright also issued estimates for Axsome Therapeutics' Q4 2026 earnings at ($0.27) EPS, Q1 2027 earnings at ($0.16) EPS and Q2 2027 earnings at $0.60 EPS.

Several other equities analysts have also commented on the stock. Robert W. Baird lowered their price objective on shares of Axsome Therapeutics from $246.00 to $220.00 and set an "outperform" rating for the company in a research report on Tuesday, November 3rd. Needham & Company LLC upped their target price on shares of Axsome Therapeutics from $267.00 to $268.00 and gave the company a "buy" rating in a research report on Tuesday, August 11th. Guggenheim lowered their price target on shares of Axsome Therapeutics from $275.00 to $250.00 and set a "buy" rating for the company in a report on Tuesday, November 3rd. BMO Capital Markets initiated coverage on Axsome Therapeutics in a research report on Monday, July 20th. They issued an "outperform" rating and a $310.00 price target for the company. Finally, Truist Financial boosted their price objective on Axsome Therapeutics from $200.00 to $285.00 and gave the stock a "buy" rating in a research note on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $267.58.

Axsome Therapeutics Stock Up 5.2%

NASDAQ AXSM opened at $140.97 on Wednesday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 1.34 and a current ratio of 1.42. The company has a market capitalization of $7.42 billion, a P/E ratio of -46.07 and a beta of 0.86. Axsome Therapeutics has a one year low of $123.00 and a one year high of $260.19. The stock has a 50 day moving average price of $175.16 and a 200-day moving average price of $197.37.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.38. The business had revenue of $259.69 million during the quarter, compared to analysts' expectations of $249.19 million. Axsome Therapeutics had a negative return on equity of 198.73% and a negative net margin of 18.18%. The firm's revenue for the quarter was up 51.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.94) EPS.

Hedge Funds Weigh In On Axsome Therapeutics

Several hedge funds have recently added to or reduced their stakes in AXSM. BlackRock Inc. bought a new position in shares of Axsome Therapeutics during the second quarter valued at approximately $759,695,000. Hillsdale Investment Management Inc. purchased a new stake in shares of Axsome Therapeutics in the first quarter worth approximately $9,019,000. OneDigital Investment Advisors LLC purchased a new stake in shares of Axsome Therapeutics in the second quarter worth approximately $1,906,000. Baird Financial Group Inc. bought a new stake in shares of Axsome Therapeutics during the 2nd quarter worth approximately $2,497,000. Finally, Lisanti Capital Growth LLC bought a new stake in shares of Axsome Therapeutics during the 2nd quarter worth approximately $5,097,000. 81.49% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Axsome Therapeutics

In other news, COO Mark Jacobson sold 10,000 shares of the stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $208.65, for a total value of $2,086,500.00. Following the sale, the chief operating officer owned 10,000 shares of the company's stock, valued at approximately $2,086,500. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 20.60% of the company's stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau. Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.